Medicine
Cholestyramine Light 4 g/4.8 g powder for oral suspension
Cholestyramine Light 4 g/4.8 g powder for oral suspension is a prescription medicine containing Cholestyramine for oral use, marketed by TAGI Pharma, with its source record on the US FDA register. It is available on request for export supply from India to licensed hospitals, importers and physicians.
Availability
Export supply from India to licensed buyers
Typical lead time
On request
Counted from payment and complete documents
Shipping
Ambient
Store at 20°C to 25°C (68° to 77°F).
Key facts
- Active ingredient (INN)
- Cholestyramine
- Brand
- Cholestyramine Light
- Strength
- 4 g/4.8 g
- Dosage form
- Powder for oral suspension
- Route
- Oral
- Packs
- 201.6 g
- Marketing authorisation holder
- TAGI Pharma
- Manufacturer
- TAGI Pharma
- Origin register
- US FDA, United States
- Storage
- Store at 20°C to 25°C (68° to 77°F).
- Cold chain
- Not required on record
- Prescription status
- Prescription only
- Controlled substance
- Not recorded as controlled
- ATC code
- C10AC01 Cholestyramine
- HS code (indicative)
- 3004.90Indicative only. Your customs broker confirms the final tariff code.
- Marketing category
- marketed
- Marketed since
- 12 November 2020
- Identifiers
- RxCUI 1801279DailyMed set ID eb85a2c8-cdc3-48bb-844d-e220ae3701a0NDC 51224-009Application ANDA209599
Record updated 12 November 2026
Documents available
Documents that can be provided with this medicine. Your regulator may ask for more, and the quote lists the full set.
No document list is recorded for this medicine yet. Tell us which documents your regulator needs (for example a CoA, COPP or GMP certificate) when you request a quote.
Packs
| Pack | Code | Labeler | Marketed since |
|---|---|---|---|
| 201.6 g in 1 can | 51224-009-10 | TAGI Pharma | 12 November 2020 |
Status by register
Where this medicine is registered, from the source record and the regulator data we hold. Ask us about a country that is not listed.
| Register | Status | Source |
|---|---|---|
| US FDA | Listed, marketed | Source record for this pageChecked 12 November 2026 |
| US FDA | First approved 3 August 1973 | Drugs@FDA |
| EU (EMA) | Not recorded | — |
| India (CDSCO) | Not yet confirmed against CDSCO approval lists | — |
| United States | Registered | US FDA (NDC directory, openFDA)Checked 12 November 2026 |
Import route
Pick the destination country to see the legal import route, who applies and typical timelines, from our import guide for that country.
Import guides are available for 25 countries. Pick one to see its route summary.
BrazilColombiaEgyptEthiopiaGhanaIraqKazakhstanKenyaAll import guides
Alternatives
Other makers and brands of Cholestyramine 4 g/4.8 g powder for oral suspension.
Other strengths and forms of Cholestyramine
Clinical summary
Cholestyramine is a bile acid sequestrant indicated as adjunctive therapy to diet for the reduction of elevated serum cholesterol in patients with primary hypercholesterolemia (elevated low density lipoprotein [LDL] cholesterol) who do not respond adequately to diet. MedsAcross supplies Cholestyramine for export from India to licensed hospitals, importers and physicians acting for named patients, with the documents each country requires.
Information from the US FDA prescribing information, retrieved 12 November 2026. Not yet medically reviewed.How we review
Read about CholestyramineFor healthcare professionals and buyers. This is not medical advice. Treatment decisions belong to the prescriber.
Data sources
- DailyMed label record · Checked 12 November 2026
- CHOLESTYRAMINE prescribing information (Zydus Lifesciences) · U.S. National Library of Medicine, DailyMed
Need Cholestyramine Light 4 g/4.8 g powder for oral suspension for your hospital or patient?
Send one request with the destination country and quantity. We confirm availability, lead time and the documents your regulator needs.